胃癌诊断和进展中的CEA,CA19-9和CA72-4:一个中国回顾性病例对照研究
Clinical laboratory
|April 10, 2025
概括
血清生物标志物如CEA,CA19-9和CA72-4在诊断胃癌 (GC) 或预测其进展和复发方面具有有限的效用. 结合这些标记物并没有显著提高诊断准确度.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 生物标志物研究 生物标志物研究
背景情况:
- 血清生物标志物的诊断和预后价值,包括癌胚抗原 (CEA),碳水化合物抗原 (CA) 19-9和CA72-4,在胃癌 (GC) 中尚未得到充分确立.
- 它们在诊断,进展预测和复发监测方面的有效性需要进一步调查.
研究的目的:
- 评估血清CEA,CA19-9和CA72-4在胃癌诊断中的临床实用性.
- 评估这些生物标志物的预测瘤进展的能力,包括淋巴结转移和远程转移.
- 为了确定这些生物标志物是否可以有效地监测治愈性胃切除术后的复发.
主要方法:
- 一项涉及564名胃癌患者和529名患有良性胃病的对照者的回顾性研究.
- 收集和分析临床数据和CEA,CA19-9和CA72-4.4的血清水平.
- 接收器操作特征 (ROC) 曲线分析以评估诊断性能.
主要成果:
- 血清中位数CEA,CA19-9和CA72-4的度在GC患者中明显高于对照组 (p < 0.001).
- 个别生物标志物的AUC值很小 (0.565-0.633),它们的组合产生了略有改善的AUC值0.652,敏感度为39.15%,特异性为86.93%.
- 生物标志物水平与病理阶段相关,但转移和复发的预测值有限;手术前水平在复发和没有复发的患者之间没有显著差异.
结论:
- 血清CEA,CA19-9和CA72-4对于诊断胃癌是不够准确的,即使结合起来.
- 这些生物标志物表现出预测晚期疾病,淋巴结转移或远程转移的能力不佳.
- 血清生物标志物测量不太可能有效地识别治疗性激进胃切除术后的复发.
相关概念视频
01:30Serum Laboratory Studies, Stool Test, Breath Test
257
Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...
257
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
69
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
69